6.2.1. deferred treatment (watchful waiting/active surveillance). prevalence cancer cells prostate much higher risk dying pca, together increased rate early detection small tumours introduction psa, distinct risk over-diagnosis subsequent over-treatment disease (chapter 3.1 epidemiology) . available radical pca treatment options may cause significant side effects conservative treatment options needed patients low risk pca death symptomatic progression pca. data studies conducted patients undergo local treatment 25 years follow-up, endpoints os css, available. several series shown consistent css rate 82–87% ten years , 80–95% t1/t2 isup grade group ≤ 2 pcas . three studies data beyond 15 years, css 80%, 79% 58% respectively , two reported 20-year css rates 57% 32% . observed heterogeneity outcomes due different inclusion criteria, older studies pre-psa era showing worse outcomes . addition, many patients classified isup grade group 1 would classified isup grade group 2–3 based 2005 gleason classification, suggesting above-mentioned results considered minimal current outcomes would favourable. patients well-, moderately- poorly-differentiated tumours 10-year css rates 91%, 90% 74%, respectively, correlating data pooled analysis . screen-detected localised pca also lead-time bias, resulting higher rate early detected pca, also even higher risk detecting clinically insignificant pca never would caused problems . cancer-specifc survival untreated screen-detected pca patients isup grade groups 1–2 therefore likely even favourable pca detected reasons. consequently, high proportion men psa-detected pca suitable conservative management active surveillance (as) watchful waiting (ww). decision choose ww independent tumour stage, mainly dependent patient factors/life expectancy, approach may include patients isup grade groups (see chapter 6.2.1.1). high css rates localised pca requires life expectancy least ten years considered mandatory benefit active treatment. co-morbidity important age predicting life expectancy men pca. increasing co-morbidity greatly increases risk dying non-pca-related causes. analysis 19,639 patients aged > 65 years given curative treatment, men cci score ≥ 2 died competing causes ten years follow-up regardless age time diagnosis. tumour aggressiveness little impact os suggesting patients could spared biopsy diagnosis cancer. men cci score ≤ 1 low risk death ten years, especially well- moderately-differentiated lesions . additionally, protect trial (see 6.2.1.2), prostate cancer-related death 3% 15 years compared death cause 21.7% patients, numbers validated two large population-based studies canada sweden [474-476]. estimation competing benefits active versus conservative treatment death cause ten 15 years estimated using predict prostate tool (available https://prostate.predict.nhs.uk/), developed using registry data uk external validation endorsed national institute health care excellence uk . highlights importance assessing co-morbidity even considering biopsy, also advising patient pca diagnosis optimal treatment him. two distinct strategies conservative management aim reduce over-treatment: ww (table 6.2.1). table 6.2.1: definitions active surveillance watchful waiting definitions active surveillance watchful waitingactive surveillancewatchful waitingtreatment intentcurativepalliativefollow-uppre-defined schedulepatient-specificassessment/markers* useddre, psa, mri recruitment, re-biopsyannual (biannual) psa dre significant psa-riselife expectancy> ten years< ten yearsaimminimise treatment-related toxicity without compromising survival, pca indolent unlikely cause symptoms even long life expectancyminimise treatment-related toxicity without compromising survival, lifespan limited pca unlikely cause symptomseligible patientslow- selected intermediate-risk patientscan apply patients stages dre = digital rectal examination; psa = prostate-specific antigen; mri = magnetic resonance imaging.*molecular markers and/or psma-pet/ct (-mri) may used.